Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have significantly improved the overall survival of patients with NSCLC, and are approved as first-line treatments for patients with the EGFR activating mutation 3. Here, EGFR is linked to non-small cell lung carcinoma.